Withings ECG-app Study

Sponsor
Withings (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05316350
Collaborator
Syntactx (Other)
632
2
2
4
316
78.8

Study Details

Study Description

Brief Summary

The aim of the study is to evaluate the performance of Withings HWA10 with embedded Withings ECG-app in the automatic detection of atrial fibrillation

Condition or Disease Intervention/Treatment Phase
  • Device: Electrocardiogram recording
  • Device: Electrocardiogram recording
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
632 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Validation of HWA10 With Withings ECG-app for the Detection of Atrial Fibrillation
Anticipated Study Start Date :
Apr 1, 2022
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Aug 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Atrial Fibrillation

Device: Electrocardiogram recording
ECG recording with investigational device

Device: Electrocardiogram recording
ECG recording with reference device

Experimental: Normal Sinus Rhythm

Device: Electrocardiogram recording
ECG recording with investigational device

Device: Electrocardiogram recording
ECG recording with reference device

Outcome Measures

Primary Outcome Measures

  1. Co-primary outcomes [4 months]

    Sensitivity (percentage of true positives) in detecting AF from conclusive recordings generated by the software under test, that is recordings resulting in a classification of AF or SR by the SUT, compared to the reference 12-lead ECG.

  2. Co-primary outcomes [4 months]

    Specificity (percentage of true negatives) in detecting AF from conclusive recordings generated by the software under test, that is recordings resulting in a classification of AF or SR by the SUT, compared to the reference 12-lead ECG.

Secondary Outcome Measures

  1. Evaluation of the classification into heart rate subgroups [4 months]

    The classification into heart rate subgroups will be evaluated for the pairs of strips such that the rhythm classification of the 12-lead ECG is either SR or AF and such that the strip generated by the SUT is classified as either SR or AF. The evaluation will be assessed with the concordance of classifications, i.e. the percentage P of identical classifications by the SUT and the reference method, into each of the four following subgroups: SR with a HR between 50 and 99 bpm SR with a HR between 100 and 150 bpm AF with a HR between 50 and 99 bpm AF with a HR between 100 and 150 bpm

  2. Clinical Equivalence of ECG waveforms [4 months]

    Clinical Equivalence of ECG waveforms will be qualitatively and quantitatively assessed between the 6-leads generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG by a board of certified cardiologists: The visibility and polarity of the P waves, QRS complexes and T waves will be determined by cardiologists and according to a set of predetermined rules. For each type of wave (P, QRS and T),

  3. Clinical Equivalence of ECG waveforms [4 months]

    The durations of the QT intervals, QRS complex widths, and PR intervals will be measured by cardiologists with a caliper and according to a set of predetermined rules for each of the 6 leads of the strips generated by the SUT and the leads I, II, III, aVR, aVL, aVF of the 12-lead ECG.

  4. Heart Rate equivalence [4 months]

    heart rate will be determined by independent cardiologists, or cardiac technicians supervised by cardiologists, from each six-channel strip recorded with the SUT and from each lead I, II, III, aVR, aVL, aVF of the 12-lead reference ECG

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or female who are 22 years of age or older

  • Subject able to read, understand, and provide written informed consent

  • Subject willing and able to participate in the study procedures as described in the consent form

  • Subject able to communicate effectively with and willing to follow instructions from the study staff

  • Have a wrist circumference between 140 mm and 210 mm (measured at "band center" on the preferred wrist, 1cm from the bone. This location is determined by asking the volunteer to put on a normal wrist-watch and marking the skin with a pen/marker to outline the edges of the band.)

Exclusion Criteria:
  • Vulnerable subject with regard to regulations in force

  • Subject who is deprived of liberty by judicial, medical or administrative decision,

  • Underage subject,

  • Legally protected subject, or subject who is unable, linguistic or psychic incapacity, to sign the written informed consent form,

  • Subject within several of the above categories,

  • Subject who refused to participate in the study,

  • Subject mentally impaired resulting in limited ability to cooperate

  • Subject in physical incapacity to wear a watch on one wrist and place the other hand on top of the watch

  • Subject with electrical stimulation by pacemaker

  • Patient with pathologic disorder that may affect motricity resulting in significant tremor that prevents subject from being able to hold still (e.g Parkinson disease)

  • Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, may increase the risk to the subject or renders data uninterpretable (e.g., recent or ongoing unstable angina, decompensated heart failure, active myocarditis or pericarditis)

  • Acute pulmonary embolism or pulmonary infarction, within 90 days of screening

  • Stroke or transient ischemic attack within 90 days of screening

  • Active life-threatening rhythms as determined by the investigator (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block).

  • History of abnormal life-threatening rhythms (ventricular tachycardia, ventricular fibrillation, 3 rd -degree heart block)

  • Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis on both wrists or over electrode attachment sites

  • Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands primarily used in wrist worn fitness devices

Contacts and Locations

Locations

Site City State Country Postal Code
1 Columbia University Irving Medical Center/ NewYork Presbyterian Hospital New York New York United States 10032
2 Columbia University Irving Medical Center New York New York United States 10065

Sponsors and Collaborators

  • Withings
  • Syntactx

Investigators

  • Principal Investigator: Elaine WAN, MD, Columbia University Irving Medical Center/ NewYork Presbyterian Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Withings
ClinicalTrials.gov Identifier:
NCT05316350
Other Study ID Numbers:
  • HWA10-ECG
First Posted:
Apr 7, 2022
Last Update Posted:
Apr 7, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Withings
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 7, 2022